Trial · NCT06847126
Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess
NCT06847126, Phase 3, Recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess. Trials, record NCT06847126. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06847126
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess
- NCT number
- NCT06847126
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 220 participants, estimated
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Conditions
- Liver Abscess
- Interventions
Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks, Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks, Standard medical care
- First posted
- 2025-02-26
- Last updated
- 2025-04-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure | 8 weeks | "clinical cure" is defined as defined as participants becoming asymptomatic with fever resolution for ≥48 hours, including USG demonstrating no drainable or aspiratable collection in the liver along with removal of the pigtail catheter if any. |
| Primary | Treatment failure | 8 weeks | "Treatment failure" is defined as the fulfilling of any one or more of the following conditions: 1. Persistently symptomatic even after 72 h of empirical antimicrobial therapy and percutaneous aspiration or drainage of the hepatic collection 2. Emergence of fresh or additional collection in the liver during the course of empirical antimicrobial therapy 3. Emergence of shock and or new onset organ failure (Encephalopathy, ARDS, AKI, MODS) during the course of therapy, leading to modification of oral antimicrobials to intravenous antimicrobials or up gradation of the ongoing intravenous antimicrobials 4. If pus culture demonstrates growth of microorganism which is not sensitive to the ongoing antimicrobials (intravenous Beta-lactam or oral Cefixime) along with inadequate clinical response to the therapy 5. Participants requiring persistent drainage or repeated aspiration of the abscess even after 4 weeks of empirical antimicrobial therapy |
| Secondary | Duration of the therapy | 8 weeks | Number of days of empirical antimicrobial therapy is required to achieve clinical cure |
| Secondary | Need for prolong antibiotics therapy | 8 weeks | Asymptomatic participants requiring persistent drainage or repeated aspiration of the abscess even after 2 weeks of empirical antimicrobial therapy to achieve clinical cure |
| Secondary | Duration of hospital stay | 8 weeks | Number of days receiving in-hospital medical care |
| Secondary | Readmission | 8 weeks | Participants requiring repeated admission with in-hospital medical care to achieve clinical |
| Secondary | Recurrence of liver abscess | 8 weeks | Emergence of new liver abscess after achieving clinical cure during 8 weeks of follow up |
| Secondary | Adverse drug reaction (ADR) | 8 weeks | Incidence of adverse drug reaction related to the ongoing antimicrobial therapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06847126
GET https://conductscience.org/api/trials/v1/NCT06847126/registered